In this podcast, we will explore approaches to non-small cell lung cancer
(NSCLC) with and without targetable mutations. NSCLC is the most
common type of lung cancer, and while significant strides have been
made in its management, there are still areas of unmet need. Our
speakers, Luis Raez, MD, FACP, FCCP, from Memorial Healthcare System in
Pembroke Pines, FL, Melissa Johnson, MD, Sarah Cannon Research
Institute, Nashville, TN, and Jorge Nieva, MD, from the University of
California, San Francisco, CA, share the current treatment landscape for
patients with NSCLC with and without targetable mutations, highlighting
recent trial results, and challenges associated with sequencing of
therapies.